Lightnews — Scholar-powered news

su2cscience.bsky.social @su2cscience.bsky.social · 22h

Will Freed-Pastor from @danafarber.bsky.social gave a phenomenal presentation on cryptic #antigens and their potential as targets for TCR-based therapies at the @theaacr.bsky.social Special Conference in #PancreaticCancer Research.

1

su2cscience.bsky.social @su2cscience.bsky.social · 17d

3

su2cscience.bsky.social @su2cscience.bsky.social · 17d

The 18th @theaacr.bsky.social Conference on the Science of #HealthDisparities took place in Baltimore from September 18-21. A special session held on Saturday featured a panel discussion, grantees, advocates, and other members of the @su2c.bsky.social community. Thanks to all in attendance!

1 1 3

su2cscience.bsky.social @su2cscience.bsky.social · 23d

Michael Goggins, Maria Irene Canto, and a team of @su2c.bsky.social and @lustgarten.org funded researchers at @hopkinsmedicine.bsky.social have found a link between dilation of the #pancreatic duct and the development of #pancreaticcancer in high-risk individuals. www.ghadvances.org/article/S277...

Mild dilatation of the main pancreatic duct is a risk factor for progression to pancreatic cancer in high-risk individuals

Mild dilatation of the main pancreatic duct (MPD) can be an early indicator of an obstructing mass, but its clinical significance in asymptomatic high-risk individuals (HRI) undergoing surveillance ha...

www.ghadvances.org

1

su2cscience.bsky.social @su2cscience.bsky.social · 27d

The Data for Children's and Young People's Cancer Programme Award is a new partnership between @su2c.bsky.social and @cancerresearchuk.org to support data-driven solutions to common challenges in this space.
More information: cruk.ink/4njVxWU
Informational webinar: cruk.ink/4gdAcw9

1

su2cscience.bsky.social @su2cscience.bsky.social · Aug 12

The @su2c.bsky.social Catalyst®[email protected]‬ Team lpublished the results of Arm C of the NeoACTIVATE trial in the European Journal of Cancer showing that neoadjuvant atezolizumab/tiragolumab is a promising treatment regimen in stage III melanoma www.ejcancer.com/article/S095...

NeoACTIVATE Arm C: Phase II trial of neoadjuvant atezolizumab and tiragolumab for high-risk operable Stage III melanoma

Neoadjuvant ± adjuvant immunotherapy improves event-free survival (EFS) versus adjuvant immunotherapy alone for high-risk resectable Stage III melanoma. However, the optimal regimen balancing efficacy...

www.ejcancer.com

1

su2cscience.bsky.social @su2cscience.bsky.social · Jul 29

A study in NatureComms uses #ML and a clinicogenomic dataset generated by the @su2c.bsky.social -@ ‪@acscan.bsky.social‬ Lung Cancer Dream Team to improve immune checkpoint monotherapy or combination #immunotherapy-#chemotherapy for patients with #NSCLC. www.nature.com/articles/s41...

Machine-learning driven strategies for adapting immunotherapy in metastatic NSCLC - Nature Communications

The approval of first line immune checkpoint blockade (ICB) has improved outcomes for patients with metastatic non-small cell lung cancer (mNSCLC), however, whether patients would benefit more from IC...

www.nature.com

1

su2cscience.bsky.social @su2cscience.bsky.social · Jul 25

Request for Applications! The @su2c.bsky.social - @CRUK Prevention, Early Stage Detection, and Interception of Recurrence Challenge is now open! For more information, click the link below or search Stand Up To Cancer in Proposal Central under Grant Opportunities. standuptocancer.org/science/gran...

1

su2cscience.bsky.social @su2cscience.bsky.social · Jul 21

According to a paper published in ‪@cp-cancercell.bsky.social‬ by the @su2c.bsky.social‬ Colorectal Cancer Dream, they have been able to use mutagenic agents to engineer an MMRd genotype in immunoresistant cells to generate an immunogenic phenotype
www.cell.com/cancer-cell/...

Induction of a mismatch repair deficient genotype by tailored chemical mutagenesis in experimental models of cancer

Rousseau et al. show that tailored mutagenic chemical treatment induces a mismatch repair deficient genotype by epigenetic Msh2 silencing leading to potent immune response in immunoresistant tumor mod...

www.cell.com

2

su2cscience.bsky.social @su2cscience.bsky.social · Jul 16

The GBM chatbot is going live on the @su2c.bsky.social website on 7/16. This AI companion was developed by Jason Binder after his wife was diagnosed with glioblastoma to help patients and family members to understand glioblastoma, explore options, and feel less alone on this journey. #GBMDay

1

su2cscience.bsky.social @su2cscience.bsky.social · Jul 15

@su2c.bsky.social Convergence 3.1416 Research Team member Raul Rabadan published a review in @CR_AACR examining examples of noncoding mutations in cancer and comparing key AI models developed over the last decade for uncovering cancer-associated noncoding mutations. aacrjournals.org/cancerres/ar...

Illuminating the Noncoding Genome in Cancer Using Artificial Intelligence

Abstract. Understanding the vast noncoding cancer genome requires cutting-edge, high-resolution, and accessible strategies. Artificial intelligence is revolutionizing cancer research, enabling advance...

aacrjournals.org

1 2

su2cscience.bsky.social @su2cscience.bsky.social · Jul 14

A project initiated by the @su2c.bsky.social Breast Cancer Dream Team was published in npj precision oncology utilizing cohort-level and individual networks to predict best response in patients with metastatic triple negative breast cancer www.nature.com/articles/s41...

www.nature.com

1

su2cscience.bsky.social @su2cscience.bsky.social · Jul 11

New Request for Applications! The @su2c.bsky.social Lung Cancer Early Detection Challenge is open! For information, please click the link below or search Stand Up To Cancer in Proposal Central under Grant Opportunities. #LungCancer #EarlyDetection #StandUpToCancer standuptocancer.org/science/gran...

Grant and Award Opportunities | Stand Up To Cancer®

Stand Up To Cancer (SU2C) grants and awards fund cancer research projects that address critical problems in patient care and deliver near-term patient benefit through both individual and collaborative...

standuptocancer.org

1

su2cscience.bsky.social @su2cscience.bsky.social · Jun 23

The @su2c.bsky.social‬ Multiple Myeloma Dream Team published in ‪@natgenet.nature.com describing their MM precursor genomic map in order to better inform risk assessment and monitoring of MM precursor conditions. www.nature.com/articles/s41...

Genomic landscape of multiple myeloma and its precursor conditions - Nature Genetics

The genomic features of precursor conditions of multiple myeloma provide multiple biological insights into disease origins and evolution, together with opportunities to identify those at highest risk ...

www.nature.com

2

su2cscience.bsky.social @su2cscience.bsky.social · Jun 9

Check out the upcoming New York Academy of Sciences Frontiers in Cancer Immunology Symposium. The event features several current and former @SU2C – funded researchers including @bengrbm.bsky.social, Jim Allison, Antoni Ribas, Taha Merghoub, and Padmanee Sharma. #immunology #cancer

1 1

su2cscience.bsky.social @su2cscience.bsky.social · May 29

A new method shows unexpected behavior in molecular crowding during cell state transitions suggests density as a biomarker for precision medicine per a paper in @natbiomedeng.nature.com‬ from @su2c.bsky.social‬ Convergence 3.1416 Research Teams Scott Manalis ‪@mit.edu‬ www.nature.com/articles/s41...

High-throughput single-cell density measurements enable dynamic profiling of immune cell and drug response from patient samples - Nature Biomedical Engineering

A platform for profiling single-cell density reveals insights into the regulation of cell density homeostasis and patient drug responses.

www.nature.com

4

su2cscience.bsky.social @su2cscience.bsky.social · May 22

cfDNA approaches can identify therapeutic response of #pancreaticcancer patients per a paper from Victor Velculescu of the @su2c.bsky.social‬[email protected] and @su2c.bsky.social y.social‬[email protected]‬[email protected] Dream Teams https://www.science.org/doi/10.1126/sciadv.ads5002

Genome-wide analyses of cell-free DNA for therapeutic monitoring of patients with pancreatic cancer

Noninvasive mutation-based and fragmentation-based cfDNA approaches can identify response to therapy in pancreatic cancer.

www.science.org

1

su2cscience.bsky.social @su2cscience.bsky.social · May 21

Work from the ‪@su2c.bsky.social‬Convergence 3.1416 Research Team led by Dan Littman from NYU and a Sharp Award was published in @nature.com‬ describing how dendritic cells are able to regulate T cell responses to food and microbes and contribute to food tolerance www.nature.com/articles/s41...

PRDM16-dependent antigen-presenting cells induce tolerance to gut antigens - Nature

A subset of antigen-presenting cells of myeloid origin that require PRDM16 and RORγt regulates T cell function to enable immune tolerance of food and commensal gut microorganisms.

www.nature.com

1

su2cscience.bsky.social @su2cscience.bsky.social · May 15

Gerrit Meijer from the @su2cscience.bsky.social-#KWF MEDOCC team presented the Team’s work in developing the multi-target FIT test for colorectal cancer at the @nkinl.bsky.social Early Cancer Detection Conference #StandUpToCancer #NetherlandsCancerInstitute #colorectalcancer

1 2

su2cscience.bsky.social @su2cscience.bsky.social · May 5

80% of patients with early stage dMMR solid tumors treated with dostarlimab avoided surgery, chemotherapy or radiation after treatment per a paper published in @nejm.org by Andrea Cercek @mskcancercenter.bsky.social of the @su2c.bsky.social Colorectal Cancer Dream Team
www.nejm.org/doi/full/10....

Nonoperative Management of Mismatch Repair–Deficient Tumors | NEJM

Among patients with mismatch repair–deficient (dMMR), locally advanced rectal cancer, neoadjuvant checkpoint blockade eliminated the need for surgery in a high proportion of patients. Whether this ...

www.nejm.org

2 5

su2cscience.bsky.social @su2cscience.bsky.social · Apr 21

The @su2c.bsky.social Catalyst @genentech.bsky.socia Team published in the Journal for ImmunoTherapy of Cancer a low rate of distant metastasis differences in gut microbiome structure in patients enrolled in the NeoACTIVATE trial jitc.bmj.com/content/13/4...

Neoadjuvant cobimetinib and atezolizumab with or without vemurafenib for stage III melanoma: outcomes and the impact of the microbiome from the NeoACTIVATE trial

Background Neoadjuvant treatment has become standard for patients with high-risk operable stage III melanoma, but the optimal regimen is unknown. Targeted therapy approaches yield high pathological re...

jitc.bmj.com

1

su2cscience.bsky.social @su2cscience.bsky.social · Apr 18

Congratulation to the 2025 class of Fellows of the @theaacr.bsky.social Academy and @su2cscience.bsky.social community members Nina Bhardwaj from Mount Sinai, Stephan Grupp and Robert [email protected], Ari Melnick @weillcornell.bsky.social, William Sellers @broadinstitute.org!!

1

su2cscience.bsky.social @su2cscience.bsky.social · Mar 27

In February, members of the #StandUpToCancer - Van Andel Institute #Epigenetics Dream Team, Ben Youngblood from St. Jude Children's Research Hospital, and Kirsten Grønbaek from Rigshospitalet, presented at the AACR DNA #Methylation, Clonal Hematopoiesis, and #Cancer Special Conference in San Diego.

3

su2cscience.bsky.social @su2cscience.bsky.social · Feb 20

An new publication in @Nature by SU2C Convergence Team leaders @thevinodlab.bsky.social @bengrbm.bsky.social @mskcancercenter.bsky.social showed an individualized neoantigen mRNA vaccine for #pancreaticcancer led to prolonged survival and effector T cell responses www.nature.com/articles/s41...

RNA neoantigen vaccines prime long-lived CD8+ T cells in pancreatic cancer - Nature

In a phase 1 trial, patients with pancreatic ductal adenocarcinoma who were treated with surgery and bespoke neoantigen mRNA vaccines combined with anti-PD-L1 and chemotherapy exhibited marked lo...

www.nature.com

2 2

su2cscience.bsky.social @su2cscience.bsky.social · Feb 11

Congratulations to @su2cscience.bsky.social [email protected] Convergence Team Co-Leader @TheVinodLab on being named to the inaugural edition of the @washingtonpost.com Post Next 50, a list of up-and-coming changemakers shaping society in 2025! wapo.st/VinodBalacha...

Post Next 50

50 people shaping our society in 2025

wapo.st

1 2